Zhuhai Trinomab

珠海泰诺麦博制药股份有限公司 outlines its product pipeline under development.

珠海泰诺麦博制药股份有限公司 provides an overview of its product offerings.

珠海泰诺麦博制药股份有限公司 presents its fully natural human antibody research platform.

The page announces the first domestic approval of ritwivab, a single-antibody injection with 9-month clinical efficacy data for infant RSV protection.

The page covers IDWeek 2026 data on the RSV monoclonal antibody newduotuo, focusing on 270-day follow-up results.

The page introduces newduotuo, the first RSV monoclonal antibody globally to offer 9 months of protection, transitioning from GMP facility to clinical market.

The page lists company news under the news center section for Zhuhai Tainuo Pharmaceutical Co., Ltd.

珠海泰诺麦博制药股份有限公司 is a biotechnology company.

Zhuhai tenor Mabo Biotechnology Co., Ltd is a biotechnology company.

Zhuhai Trinomab Pharmaceutical reports **CNY 154.56 million in sales** for the first nine months of 2026, up from **CNY 30.42 million** in the same period last year. The company narrows its net loss to **CNY 302.45 million**, an improvement over the **CNY 453.36 million** loss recorded in 2025. Revenue growth contrasts with ongoing losses as the biopharmaceutical firm scales operations.

Oct 2026MarketScreenerNews article

Trinomab receives China’s approval for a long-acting prophylactic antibody offering nine months of RSV protection for newborns and infants. The treatment demonstrates greater efficacy in high-risk populations entering their first RSV season. This marks the first such prophylactic approved globally for extended infant protection.

Sep 2026InsightsNews article

Trinomab’s stock price jumps **246.82%** on its debut listing on Shanghai’s STAR Market, opening at **US$6.9** after pricing its IPO at **US$1.99 per share**. The surge propels its market valuation to over **US$3.16 billion**. The company’s strong debut reflects investor confidence in its biotech focus and market positioning.

Jul 2026dealroom.coNews article

China Medical System Holdings Limited gains exclusive commercialization rights for **Vecantoxatug**, a monoclonal antibody therapy for tetanus prevention, and **Silevimig**, a similar therapy for rabies prevention. The rights are secured through collaboration agreements with Genrix Bio. These therapies represent advancements in preventive antibody-based treatments for two globally significant infectious diseases.

Sep 2025MedPath TrialNews article